198 related articles for article (PubMed ID: 2465574)
1. Therapeutic options in renal cell carcinoma.
Buzaid AC; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 1):12-9. PubMed ID: 2465574
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
3. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
4. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
6. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
7. A survey of therapy for advanced renal cell carcinoma.
Basso M; Cassano A; Barone C
Urol Oncol; 2010; 28(2):121-33. PubMed ID: 19576800
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
10. Interferon in metastatic renal cell carcinoma.
Fosså SD
Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
[TBL] [Abstract][Full Text] [Related]
11. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
Wood CG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
[TBL] [Abstract][Full Text] [Related]
12. [Renal cancer :therapeutical dilemma].
Miron L; Ciornea L
Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):475-80. PubMed ID: 12092176
[TBL] [Abstract][Full Text] [Related]
13. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
14. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
16. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
18. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
19. [Recent management of renal cell carcinoma].
Nishio Y; Yoshida O
Gan To Kagaku Ryoho; 1988 Feb; 15(2):219-23. PubMed ID: 3257677
[TBL] [Abstract][Full Text] [Related]
20. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
